Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
Trial details
- Registry ID
- NCT04973228
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ARQ-154
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)NCT04973228 | ARQT | Phase 3 | Completed | 2022-04-06Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |